Max Stanyard

Max Stanyard is an associate director in the research and development tax incentives team and a health care/life sciences senior analyst at RSM UK. With nearly 10 years of experience, he leads the R&D health care/life sciences team from a marketing and growth perspective. His educational background in pharmacology allows him to communicate effectively with technical staff within client organizations.

5 things to know in life sciences: Week of March 23, 2026

Mar. 27, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

Each week we highlight five things affecting the life sciences industry. Here’s the latest. … READ MORE >

5 things to know in life sciences: Week of March 16, 2026

Mar. 20, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

FDA provides new guidance to replace animal testing in early drug studies. This and more in this week’s life sciences update. … READ MORE >

5 things to know in life sciences: Week of March 9, 2026

Mar. 13, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

Each week we highlight five things affecting the life sciences industry. Here’s the latest. … READ MORE >

5 things to know in life sciences: Week of March 2, 2026

Mar. 5, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

Each week we highlight five things affecting the life sciences industry. Here’s the latest. … READ MORE >

5 things to know in life sciences: Week of Feb. 23, 2026

Feb. 27, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

Each week we highlight five things affecting the life sciences industry. Here’s the latest. … READ MORE >

5 things to know in life sciences: Week of Feb. 16, 2026

Feb. 20, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

Each week we highlight five things affecting the life sciences industry. Here’s the latest. … READ MORE >

5 things to know in life sciences: Week of Feb. 9, 2026

Feb. 13, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

AI is moving from experimentation to operational core in clinical trials. This and more in this week’s life sciences update. … READ MORE >

5 things to know in life sciences: Week of Feb. 2, 2026

Feb. 6, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

The FDA launches domestic drug manufacturing precheck program. This and more in this week’s life sciences industry update. … READ MORE >

5 things to know in life sciences: Week of Jan. 26, 2026

Jan. 30, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

Four key trends reshaping strategic M&A in biopharma. This and more in this week’s life sciences industry update. … READ MORE >

5 things to know in life sciences: Week of Jan. 19, 2026

Jan. 23, 2026 by Amanda Laskey, Katherine Powers and Max Stanyard

Three technologies shaping biotech in 2026. This and more in this week’s life sciences update. … READ MORE >